酷派集團(02369.HK)供股獲認購約84.66%
格隆匯6月25日丨酷派集團(02369.HK)公吿,於2021年6月18日下午四時正,共接獲就合共30.48億股供股股份的31份有效接納及申請,佔供股項下可用供股股份總數36億股供股股份的約84.66%。
由於包銷協議所載的全部條件已獲達成,且包銷商於最後終止時限前並無終止包銷協議,供股已於2021年6月23日下午四時正成為無條件。供股所籌集的資金總額(扣除開支前)約為10億港元。
根據上述接納及申請結果,合共12.12億股額外供股股份的所有有效申請已被接納,且董事已向申請額外供股股份的各合資格股東分配所申請的額外供股股份的實際數目。預期繳足股款的供股股份將於2021年6月29日上午九時正開始在聯交所買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.